Adagio Therapeutics (ADGI) Shares Are Up 80% Since Friday. Here's Why
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Adagio Therapeutics (ADGI) Stock Now Up 70%, Stifel Says Merck's (MRK) Molnupiravir is not a Competitive Threat to ADG20
November 29, 2021 11:08 AM ESTAdagio Therapeutics (NASDAQ: ADGI) stock is up around 70% today as investors continue to bet that alternative cures are needed and vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.
Adagio shares soared in pre-open Monday after the company said its lead candidate ADG20 will retain activity against the new COVID variant Omicron.
None of the mutations present in the spike protein of the Omicron variant have been... More
Adagio Therapeutics (ADGI) Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
November 29, 2021 6:31 AM ESTAdagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single... More
